Table 3. Efficacy of HM ointment in HSV-2 genital infection model.

Drug Treatment	No. of animals	No. of animals survived	No. of death	Survival (%)	Days-to-mortality (mean±S.D. days)a	No. of vaginal samples containing HSV-2
						Before treatment	After treatment/death
HM 0.5%	20	14	06	70*b	11.15 ± 2.34*	20	07*
HM 0.25%	20	09	11	45*	9.45 ± 2.66*	20	15*
ACV 5%	20	16	04	80*	11.85 ± 1.33*	20	05*
Vaseline Base	20	02	18	10**	7.65 ± 2.87**	20	18**
Virus control	20	01	19	5	6.75 ± 1.93	20	19
Uninfected	20	20	0	100	NAc	0	0

^aAverage time for mortality to occur following infection.

^b P value from t-test between test group and virus control group. * P > 0.01; ** P < 0.05

^cNot applicable.